Micosis fungoides

  • Cristina María Uribe Betancur Instituto de Ciencias de la Salud CES
  • Isabel Restrepo Álvarez Instituto de Ciencias de la Salud CES
Palabras clave: micosis fungoides, clínica, diagnóstico y tratamiento

Resumen

La micosis fungoides es un linfoma de células T (LCCT) periférico no Hodgkin que se presenta inicialmente en la piel; representa el tipo más frecuente
de los linfomas cutáneos T y el 50% de todos los linfomas cutáneos primarios. Se caracteriza por una evolución clínica de tres estadios: máculas, placas y
tumores.

Múltiples variantes difieren de la forma clásica y son referidas como formas atípicas de la enfermedad que histológicamente se caracteriza por la proliferación de linfocitos cerebriformes y epidermotropismo.

La elección del tratamiento inicial depende del estadio de la enfermedad, del estado general del paciente y de su edad.

Biografía del autor/a

Cristina María Uribe Betancur, Instituto de Ciencias de la Salud CES

RIII Dermatología. Instituto de Ciencias de la Salud CES. Medellín.

Isabel Restrepo Álvarez, Instituto de Ciencias de la Salud CES

RIII Dermatología. Instituto de Ciencias de la Salud CES. Medellín.

Referencias bibliográficas

1. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S. EORTC Classification for Primary Cutaneous Lymphomas: A Proposal From the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997: 90 (1 ). p 354- 71.

2. Latkowski JA, Heald P. Cutaneous T Cell Lymphomas. Fitzpatrick T, Freedberg IM.Fitzpatrick's Dermatology in General Medicine, 6th ed.: McGraw - Hill, 2003, p 1537- 58.

3. MacKie, Rona M. Cutaneous lymphomas and lymphocytic lnfiltrates ROOK / WILKINSON / EBLING Textbook of Dermatology 6th ed.: Blackwell Science, 1998, p 2373-2402.

4. Siegel R, Pandolfino T, Guitar J, Rosen S, Kuzel T. Primary Cutaneous T- cell Lymphoma: Review and Current Concepts. Review. J Clin Oncol 2000; 18(5): 2908- 25.
https://doi.org/10.1200/JCO.2000.18.15.2908

5. Prince M.H , O'Keefe R, McCormack C, Ryan G, Turner H, Waring P, Baker C. Cutaneous lymphomas: Which pathological classification ?. Rewiew. Pathology 2002; 34: 36-45.
https://doi.org/10.1080/00313020120105615

6. Shapiro P.E, Pinto F.J. The Histological Spectrum of Mycosis Fungoides / Sezary Syndrome. A Review of 222 Biopsies lncluding Newly Described Patterns and the Earliest Pathologic Changes. Am J Surg Pathol 1994; 18 (7): 645-67
https://doi.org/10.1097/00000478-199407000-00001

7. Ackerman AB. Histologic Diagnosis of lnflammatory Skin Diseases: An Algorithmic Method Based on Pattern Analysis. Baltimore: Williams & Wilkins, 1997.

8. Guitar J, Kennedy J Salve R, Chmiel JS, Hsiegh Y i-Ching, Variakojis D. Histological Criteria for the Diagnosis of Mycosis Fungoides: Proposal for a Grading System to Standardize Pathology Reporting. J Cutan Patol. April 2001; 28 (4):174.
https://doi.org/10.1034/j.1600-0560.2001.028004174.x

9. Ruiz E, Jegasothy B.V, Callen J.P, Jorizzo J.L. Cutaneous T- Cell Lymphoma Dermatological Sings of Interna! Diseases. 2 ed. vol.3. Col: Corcas. 2000:165-71.

10. Naraghi Z, Seirafi H, Valikhani M, Farnaghi F, Kavusi S, Dowlati Y. Assessment of Histologic Criteria in the Diagnosis of Mycosis Fungoides. lnt J Dermatol 2003 Jan; 42(1 ):45-52.
https://doi.org/10.1046/j.1365-4362.2003.01566.x

11. Glusac EJ. Criterion by Criterion, Mycosis Fungoides. Am J Dermatopathol 2003; 25(3): 264-69. 12. Glusac EJ. Of cells and architecture: New approaches to old criteria in mycosis fungoides. J Cutan Phatol 2001; 28: 169-73.
https://doi.org/10.1034/j.1600-0560.2001.028004169.x

13. Santucci M, Biggeri A, Feller AC, Burg G. Efficacy Of Histologic Criteria for Diagnosing Early Mycosis Fungoides. Am J Surg Pathol 2000; 24 (1 ): 40-50.
https://doi.org/10.1097/00000478-200001000-00005

42. Zackheim HS. Topical and intralesional chemothera­peutic agents. En: Wolverton SE ed. Comprehensive Dermatologic Drug Therapy. Philadelphia: WB Saun­ders Company, 2001; p.595-606.

43. Zackheim HS. Topical carmustine (BCNU) for patch/plaque mycosis fungoides. Semin Dermatol 1994; 13:202-6.

44. Breneman D, Duvic M, Martín A et al. Longterm treat­ment of patients with early stage cutaneous T- cell lym­phoma bexarotene gel 1 %. Póster 229. 60 th Annual Meeting of the American Academy of Dermatology; 227 Febrero 2002; New Orleans (LA).

45. Suchin KR, Junkins- Hopkins JM, Rook AH. Treatment of stage IA cutaneous T- Cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol 2002; 138:1137-9.
https://doi.org/10.1001/archderm.138.9.1137

46. Muche JM, Born A, Sterry W, Gellrich S. lmiquimode in the treatment of cutaneous T cell lymphoma. EORTC Cutaneous Lymphoma Task Force Clinical Meeting; 13-15 junio 2003; Helsinki.

47. Ramsay DL, Lish KM, Yalowitz CB, Soter NA. Ultravio­let - B phototherapy for earlstage cutaneous T - cell lymphoma. Arch Dermatol 1992; 128:931-3.
https://doi.org/10.1001/archderm.1992.01680170063007

48. Zanolli MD. Cutaneous T-cell lymphoma. En: Zanolli MD, Feldman SR, Clark A, Fleischer A eds. Photothe­rapy treatment protocols for psoriasis and other photo­therapy responsive dermatoses. New York: Parthenon Publishing, 2000;p.107-17.

49. Clark , Dawe RS, Evans AT et al. Narrowband TL-01 phototherapy for patch- stage mycosis fungoides. Arch Dermatol. 2000;136:748-52.
https://doi.org/10.1001/archderm.136.6.748

50. Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311- nm) UV-8 therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol 1999; 135:1377-80.
https://doi.org/10.1001/archderm.135.11.1377

51. Herrmann JJ, Roenigk HH, Honigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma . Hematol Oncol Clin North Am 1995;9: 1077-88.
https://doi.org/10.1016/S0889-8588(18)30059-5

52. Herrmann JJ, Roenigk HH, Hurria A et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long­term follow- up. J Am Acad Dermatol 1995;33: 234-42.
https://doi.org/10.1016/0190-9622(95)90241-4

53. Russell-Jones R, Whittaker S. Sézary syndrome: diag­nostic criteria and therapeutic options. Semin Cutan Med Surg 2000; 19: 100-8.
https://doi.org/10.1016/S1085-5629(00)80006-1

54. Edelson R, Berger C, Gasparro F et al.Treatment of cutaneous T- cell lymphoma by extracorporeal photo­chemotherapy. N Engl J Med 1987; 316:297-303.
https://doi.org/10.1056/NEJM198702053160603

55. Heald P, Pérez M, Christensen I et al. Photopheresis therapy of cutaneous T-cell lymphoma: The Vale- New Haven hospital experience. Vale Biol Med 1989; 62:629- 38.

56. Duvic M, Hester J, Lemak A. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35:573-9.
https://doi.org/10.1016/S0190-9622(96)90683-0

57. Russell-Jones R, Fraser - Andrews E, Spittle M et al. Extracorporeal photopheresis in Sézary syndrome. Lan­ce! 1997; 350:886.
https://doi.org/10.1016/S0140-6736(05)62067-3

58. Russell- Jones R. Extracorporeal photopheresis in cu­taneous T-cell lymphoma: inoconsistent data underlie the need for randomized structures. Br J Dermatol 2000; 142:16-21
https://doi.org/10.1046/j.1365-2133.2000.03286.x

59. Jumbou O, N'Guyen JM, Tessier MH et al. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa. Br J Der­matol 1999; 140:427-31.
https://doi.org/10.1046/j.1365-2133.1999.02704.x

60. Wolff JM, Zitelli JA, Rabin BS et al. lntralesional inter­feron in the treatment of early mycosis fungoides. J Am Acad Dermatol 1985; 13:604-12.
https://doi.org/10.1016/S0190-9622(85)70205-8

61. Quesada JR, Talpaz M, Ríos A et al. Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986; 4:234-43.
https://doi.org/10.1200/JCO.1986.4.2.234

62. Koh LK, Greenspan FS, Veo PP. lnterferon- alpha in­duced thyroid dysfunction: three clinical presentations and review of the literature. Thyroid 1997; 7:891-6.
https://doi.org/10.1089/thy.1997.7.891

63. Wong SF. Oral Bexarotene in the treatment of cutaneous T-cell lymphoma. Ann Pharmacother 2001; 35:1056-65.
https://doi.org/10.1177/106002800103500903

64. Duvic M, Hymes K Helad P and cols. Bexarotene is effective and safe for treatment of refractory advenced­stage cutaneous T-cell lymphoma: multinational phase 11- 111 trial results. J Clin Oncol 2001; 19:581-93.
https://doi.org/10.1200/JCO.2001.19.9.2456

65. Duvic M, Martín AG, Kim Y et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treat­ment of refractory or persisten! early-stage cutaneous T- cell lymphoma. Arch Dermatol 2001; 137:581-93.

66. Vittorio CC, Rook AH, Fench LE et al. Therapeutic ad­vanees in biological response modifiers in the tratment of cutaneous T-cell lymphoma. BioDrugs 2001; 15:431- 7.
https://doi.org/10.2165/00063030-200115070-00002

67. Talpur R, Ward S, Apisarnthanarax N et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47: 672-84.
https://doi.org/10.1067/mjd.2002.124607

68. Olsen E, Duvic M, Frankel A et al. Pivota! phase 111 trial of to dose levels of denileukin diflitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19:376-88.
https://doi.org/10.1200/JCO.2001.19.2.376

69. Duvic M, Catre J, maize J, Frankel AE. DAB389IL2 diph­theria fusion toxin produces clinical responses in tumr stage cutaneous T cell lymphoma. Am J Hematol 1998; 58:87-90.
https://doi.org/10.1002/(SICI)1096-8652(199805)58:1<87::AID-AJH18>3.0.CO;2-2

70. Foss FM, Bacha P, Kuzel TM. Biological correlates of acute hypersensitivity events with DAB389IL-2 (deni­leukin diftitox) in cutaneous T-cell lymphoma: decrea­sed frequency and severity with steroid premedication. Clin Lymphoma 2001 ;1 :298-302.
https://doi.org/10.3816/CLM.2001.n.005

71. Flynn JM, Byrd JC. Campath-1 H monoclonal antibody therapy. Curr Opin Oncol 2000; 12:574-81.
https://doi.org/10.1097/00001622-200011000-00010

72. Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1 H monoclonal antibody in therapy for previously trea­ted low-grade non-Hodgkin · s lymphomas: a phase 11 multicenter study. European Study Group of CAMPA­TH-1 H Treatment in Low- Grade Non- Hodgkin's Lym­phoma. J Clin Oncol 1998; 16:3257-63.
https://doi.org/10.1200/JCO.1998.16.10.3257

73. Dearden CE. CAMPATH-1 H in cutaneous T-cell lym­phoma. EORTC Cutaneous Lymphoma Task Force Cli­nical Meeting; 2003 Jun 13- 15; Helsinki.

74. Jones G.W, Kacinski B.M, Wison L.D, Willemze R, et al. Total Skin Electron Radiation in the Management of Mycosis fungoides: Consensus of the European Orga­nization for Research and Treatment of Cancer (E.O.R.T.C) Cutaneous Lymphoma Project Group. J Am Acad Dermatol. 2002; 47(3): 364-70.
https://doi.org/10.1067/mjd.2002.123482

75. Case DC. Combination chemotherapy for mycosis fun­goides with cyclophosphamide, vincristine, methotrexa­te, and prednisone. Am J Clin Oncol 1984;7:453-5.
https://doi.org/10.1097/00000421-198410000-00012

76. Rosen ST, Foss FM. Chemotherapy for mycosis fun­goides and the Sezary syndrome. Hematol Oncol Clin North Am 1995;9:1109-16.
https://doi.org/10.1016/S0889-8588(18)30061-3

77. Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: Results twenty-nine patients. J Am Acad Dermatol 1996; 34:626-31.
https://doi.org/10.1016/S0190-9622(96)80062-4

78. Vonderheid EC, Sajjadian A, Kadin ME. J Methotrexa­te is effective therapy for lymphomatoid papulosis and other primy cutneous CD30-positive lymphoproliferati­ve disorders. J Am Acad Dermatol 1996;34:470-81.
https://doi.org/10.1016/S0190-9622(96)90442-9

79. Zinzani PL, Baliva G, Magagnoli M et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: ex­perience in 44 patients. J Clin Oncol 2000; 18:2603-6.
https://doi.org/10.1200/JCO.2000.18.13.2603

80. Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ. Acti­vity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study. J Nati Cancer lnst 1990;82:1353-5.
https://doi.org/10.1093/jnci/82.16.1353

81. Scarisbrick JJ, Child FJ, Clift A et al. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T­cell lymphoma. Br Dermatol 2001; 144: 1010-5.
https://doi.org/10.1046/j.1365-2133.2001.04191.x

82. Foss FM, lhde DC, Linnoila IR et l. Phase 11 trial of flu­darabine phosphate and interferon alfa-2ª in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol 1994;12:2051-9.
https://doi.org/10.1200/JCO.1994.12.10.2051

83. Foss FM. Activity of pentostatin (Nipent) in cutaneous T- cell lymphoma: single- agent and combination stu­dies. Semin Oncol 2000;27:58-63.

84. Dearden C, Matutes E, Catovsky D. Pentostatin treat­ment of cutaneous T-cell lymphoma. Oncology (Hun­tingt) 2000; 14:37-40.

85. Greiner D, Olsen EA, petroni G. Pentostatin (2 · - deoxycoformmycin) in the treatment of cutaneous T­cell lymphoma. J Am Acad Dermatol 1997;36:950-5.
https://doi.org/10.1016/S0190-9622(97)80279-4

86. Burt RK, Guitart J, Traynor A et al. Allogeneic hemato­poietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant 2000;25: 111-3.
https://doi.org/10.1038/sj.bmt.1702099

87. Chinn DM, Chow S, Kim YH, Hoppe RT. Total skin elec­trón beam therapy with or without adjúvant topical ni­trogen mustard or nitrogen mustard alone as initial treat­ment of T2 and T3 mycosis fungoides. lnt J Radiat Oncol Biol Phys 1999;43:91-8.
https://doi.org/10.1016/S0360-3016(98)00517-3

88. Zackeim HS, Amin S, Kashain- Sabet M, McMillan A. Prognosis in cutaneous T cell - lymphoma by skin sta­ge: long term survival in 489 patients. J Am Acad Der­matol 1999; 40: 418 -25.
https://doi.org/10.1016/S0190-9622(99)70491-3

89. Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock,. Prognostic factor analysis in mycosis fungoides /Sézary syndrome. J Am Acad Dermatol. 1999; 40: 914-24.
https://doi.org/10.1016/S0190-9622(99)70079-4

90. Smoller B.R, Detwiler S.P, Kohler S, Hoppe R.T, Kim Y.H. Role of histology in providing prognostic informa­tion in mycosis fungoides. Am J Dermatopathol. 1998 Jul; 25 (6):311-5.
https://doi.org/10.1111/j.1600-0560.1998.tb01751.x

91. Toro JR, Stoll HL, Stomper PC, Oseroff AR. Prognostic factors and evaluation of mycosis fungoides and Séza­ry syndrome. J Am Acad Dermatol 1997;37:58-67.
https://doi.org/10.1016/S0190-9622(97)70212-3

92. Van Doorn R, Van Haselen CW, van Voorst Vader PC et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136:504-10.
https://doi.org/10.1001/archderm.136.4.504

93. Grange F, Bagot M. Pronostic des lymphomas cutanés primitifs. Ann Dermatol Venereol 2002; 129:30-40
Cómo citar
1.
Uribe Betancur CM, Restrepo Álvarez I. Micosis fungoides. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 1 de octubre de 2005 [citado 6 de octubre de 2022];13(3):191-06. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/535

Descargas

La descarga de datos todavía no está disponible.
Publicado
2005-10-01
Sección
Sin sección en el original